Genting Xinyao (01952) welcomed two top mRNA talents to join to accelerate the implementation of the global innovation strategy

Zhitongcaijing · 2d ago

Zhitong Finance App learned that on October 9, Genting Xinyao (01952) announced the appointment of Dr. Lakshmi Srinivasan as senior vice president and head of translational medicine, and Dr. Brandon Coder as vice president of translational science and early stage research. This appointment will further strengthen Genting's Xinyao mRNA technology platform's global R&D capabilities and international cooperation layout. In the future, the company will continue to gather top international talents, integrate R&D resources, and accelerate the implementation of global innovation strategies.

Both new executives have deep industry experience and professional backgrounds. Previously, they were responsible for cancer vaccine research and development at leading global biopharmaceutical companies such as Modena, and have complete practical experience from early detection to clinical transformation and clinical development. Under the leadership of Genting Xinyao's management, the two senior scientists will focus on promoting clinical development and related business layout of the mRNA technology platform in the US around the company's global mRNA R&D strategy, and work closely with the Chinese R&D team to further empower the evolution of the mRNA technology platform.

Wu Yifang, chairman of Genting Xinyao's board of directors, said he was very happy that Dr. Srinivasan and Dr. Coder joined Genting Xinyao. The two senior scientists have deep experience in tumor vaccine research and development, translational medicine and clinical development. They will further strengthen the company's global mRNA research and development capabilities and help promote global clinical development of independent mRNA technology platforms and related product pipelines. This appointment reflects Genting Xinyao's commitment to continue to gather the world's top talents and advance the global mRNA strategy.

As one of the few biopharmaceutical companies in the world with a full-process, autonomous and controllable mRNA technology platform, Genting Xinyao has built a complete industrial chain platform covering antigen design, mRNA sequence optimization, lipid nanoparticle (LNP) targeted delivery technology to industrial production. It has end-to-end capabilities in the mRNA platform value chain and has successfully achieved clinical verification.